A drug currently being used to treat ischemic strokes may prove to be a significant advance in the treatment of tuberculosis and ulcers. In a new research report appearing online in The FASEB Journal, a compound called ebselen effectively inhibits the thioredoxin reductase system in a wide variety of bacteria, including Helicobacter pylori which causes gastric ulcers and Mycobacterium tuberculosis which causes tuberculosis. Thioredoxin and thioredoxin reductase proteins are essential for bacteria to make new DNA, and protect them against oxidative stress caused by the immune system. Targeting this system with ebselen, and others compounds like it, represents a new approach toward eradicating these bacteria.
"This new antibacterial principle provides better chances of surviving an infection," said Arne Holmgren, M.D., Ph.D., a researcher involved in the work from the Division of Biochemistry in the Department of Medical Biochemistry and Biophysics, at Karolinska Institutet in Stockholm, Sweden. "Since ebselen is also an antioxidant, the present mechanism can be described as a 'two for the price of one' antioxidant action in inflammation, and specific targeting of multi-resistant bacterial complications and sepsis."
Building on previous observations where ebselen has shown antibacterial properties against some bacteria, Holmgren and colleagues hypothesized that the bacteria sensitive to ebselen relied solely on thioredoxin and thioredoxin reductase for essential cellular processes. They investigated this by testing it on strains of E. coli with deletions in the genes for thioredoxin, thioredoxin reductase and the glutaredoxin system. They found that strains with deletions in the genes coding for glutaredoxin system were much more sensitive than normal bacteria. Researchers further tested ebselen against Helicobacter pylori and Mycobacterium tuberculosis, which both naturally lack the glutaredoxin system and are frequently resistant to many commonly used antibiotics, and found both to be sensitive to ebselen.
"As rapidly as these organisms evolve, we need new drugs sooner rather than later," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "The fact that these scientists have found a new target for killing some of the most resistant bacteria is great news, but the fact that we already have at least one drug which we could possibly use now makes the news even better."
Federation of American Societies for Experimental Biology: http://www.faseb.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Study is one of first to track where in the ocean predators pick up different chemicals
When amnesia strikes, people can forget everything about their life, including their name. But what causes memory loss? And what happens to people who lose themselves for an hour, a few months – or even for ever?
Tooth unearthed by 20-year-old volunteer hailed as major discovery by paleoanthropologist overseeing dig at Arago cave near Tautavel
Autistic children are just as good at reading emotions from the body as those without – they just don't like the closeness that interpreting emotions from faces requires
Individual cells can be made to act like tiny lasers, offering a more accurate way to tag and monitor tumour cells, for example
If you want to know the secret behind the success of Tyrannosaurus rex and its meat-eating dinosaur cousins, look no further than their teeth.
A recent article argued that sexuality is down to choice, not genetics. But the scientific evidence says otherwise, and points to a strong biological origin
When I hear the word “sabertooth”, my mind immediately jumps to the great sabercats who sliced through throats …
The Portland Press Herald reports that "Captain Eli," a rare orange lobster, will be kept at the Fisherman's Catch Café in Raymond, Maine, before Bill Coppersmith releases it back into the ocean.
A very rare genetic mutation causes some people to develop Alzheimer's in their 30s. It also makes these people the ideal candidates for tests of potential Alzheimer's drugs.